← Back to Search

Radiopharmaceutical

Participants undergoing 177Lu-PSMA-617 treatment for Prostate Cancer

N/A
Recruiting
Led By Thomas Hope, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Summary

This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean whole body tumor absorbed dose (WB Dose) across all metastatic lesions
Median PORTOS score

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants undergoing 177Lu-PSMA-617 treatmentExperimental Treatment3 Interventions
Participants undergoing PSMA targeted radioligand therapy with at least four cycles of treatment planned will undergo the following: SPECT/CTs will be performed 24 hours after the first treatment and after the fourth treatment, a tumor biopsy will be performed prior to the first 177Lu-PSMA radioligand therapy, a blood will be drawn prior to treatment for future research, and an optional tumor biopsy and blood draw for future research, may also be obtained at time of progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Blood Draw
2014
Completed Phase 4
~2350
Tumor Biopsy
2006
Completed Phase 2
~370
Single-photon emission computed tomography
2010
N/A
~50

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,551 Previous Clinical Trials
15,257,761 Total Patients Enrolled
52 Trials studying Prostate Cancer
17,405 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,875 Total Patients Enrolled
566 Trials studying Prostate Cancer
529,684 Patients Enrolled for Prostate Cancer
Prostate Cancer FoundationOTHER
48 Previous Clinical Trials
2,742 Total Patients Enrolled
28 Trials studying Prostate Cancer
1,865 Patients Enrolled for Prostate Cancer
~10 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top